Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

  title={Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.},
  author={Neil L. Spector and Kimberly L. Blackwell},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={27 34},
PURPOSE Targeted therapy with the humanized monoclonal antibody trastuzumab has become a mainstay for human epidermal growth factor receptor 2 (HER2) -positive breast cancer (BC). The mechanisms of action of trastuzumab have not been fully elucidated, and data available to date are reviewed here. The impact of the mechanisms of action on clinical benefit also is discussed. METHODS An extensive literature review of trastuzumab and proposed mechanisms of action was performed. RESULTS At least… CONTINUE READING
186 Citations
114 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 186 extracted citations


Publications referenced by this paper.
Showing 1-10 of 114 references

Phase II trial of trastuzumab and KOS-953 (tanespimycin) in patients with HER2-positive breast cancer: Preliminary results

  • S Modi, A Stopeck, HM Linden
  • Breast Cancer Res Treat 100:S72, 2006
  • 1102
Highly Influential
4 Excerpts

A report of cardiac events in a phase II clinical study using trastuzumab combined with pertuzumab in HER2-positive metastatic breast cancer (MBC)

  • CC Portera, JM Walshe, N Denduluri
  • J Clin Oncol 25:39s, 2007
  • 1028
Highly Influential
4 Excerpts

Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-positive early breast cancer patients: Second interim efficacy analysis

  • DJ Slamon, W Eiermann, N Robert
  • Breast Cancer Res Treat 100,
  • 2006
Highly Influential
3 Excerpts

A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2-positive metastatic breast cancer progressing on trastuzumab therapy

  • JA O’Shaughnessy, KL Blackwell, H Burstein
  • J Clin Oncol 26:44s, 2008
  • 1015
Highly Influential
3 Excerpts

A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2 metastatic breast cancer

  • S Vukelja, H Rugo, C Vogel
  • Cancer Res 69:71s,
  • 2009
2 Excerpts

C-MYC amplification and correlation with patient outcome in early stage HER2 breast cancer from the NCCTG adjuvant intergroup trial N9831

  • EA Perez, MM Reinholz, AC Dueck
  • Cancer Res 69:76s,
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…